Log In
BCIQ
Print this Print this
 

TSR-042 (formerly ANB011)

  Manage Alerts
Collapse Summary General Information
Company AnaptysBio Inc.
DescriptionAnti-PD-1 mAb
Molecular Target Programmed cell death 1 (PD-1) (PDCD1) (CD279)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors
Regulatory Designation
PartnerTesaro Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$17.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/17/2014

Undisclosed

$17.0M

Undisclosed

Get a free BioCentury trial today